Use of atypical antipsychotics in refractory depression and anxiety

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics. Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment-resistant unipolar depression, with reported remission rates of 61% to 76%. Olanzapine in combination with fluoxetine is safe and effective in patients with bipolar depression and those with fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based on the available literature.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalJournal of Clinical Psychiatry
Volume66
Issue numberSUPPL. 8
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Depressive Disorder
Antipsychotic Agents
Anxiety
Fluoxetine
olanzapine
Bipolar Disorder
Second-Generation Antidepressive Agents
Fluvoxamine
Paroxetine
Citalopram
Risperidone
Clozapine
Serotonin Uptake Inhibitors
Antidepressive Agents
Therapeutics
Placebos
Depression
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Use of atypical antipsychotics in refractory depression and anxiety. / Nemeroff, Charles.

In: Journal of Clinical Psychiatry, Vol. 66, No. SUPPL. 8, 01.12.2005, p. 13-21.

Research output: Contribution to journalArticle

@article{0555492292a74096a2da40a3dad353f6,
title = "Use of atypical antipsychotics in refractory depression and anxiety",
abstract = "Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics. Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment-resistant unipolar depression, with reported remission rates of 61{\%} to 76{\%}. Olanzapine in combination with fluoxetine is safe and effective in patients with bipolar depression and those with fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based on the available literature.",
author = "Charles Nemeroff",
year = "2005",
month = "12",
day = "1",
language = "English",
volume = "66",
pages = "13--21",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 8",

}

TY - JOUR

T1 - Use of atypical antipsychotics in refractory depression and anxiety

AU - Nemeroff, Charles

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics. Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment-resistant unipolar depression, with reported remission rates of 61% to 76%. Olanzapine in combination with fluoxetine is safe and effective in patients with bipolar depression and those with fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based on the available literature.

AB - Treatment options for bipolar depression and treatment-resistant unipolar depression include augmentation of antidepressant therapy with a nonantidepressant drug, including atypical antipsychotics. Risperidone is effective in combination with fluvoxamine, paroxetine, or citalopram in treatment-resistant unipolar depression, with reported remission rates of 61% to 76%. Olanzapine in combination with fluoxetine is safe and effective in patients with bipolar depression and those with fluoxetine-resistant unipolar depression. Ziprasidone and aripiprazole augmentation of various selective serotonin reuptake inhibitors has been reported to be effective in refractory unipolar depression in open-label studies. Data on use of quetiapine or clozapine as augmentation therapy for depression or anxiety are not yet available. Further double-blind, placebo-controlled studies of augmentation of antidepressants with atypical antipsychotics in refractory depression and anxiety are justified based on the available literature.

UR - http://www.scopus.com/inward/record.url?scp=29344438594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344438594&partnerID=8YFLogxK

M3 - Article

C2 - 16336032

AN - SCOPUS:29344438594

VL - 66

SP - 13

EP - 21

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 8

ER -